Manufacturers: Contineum Therapeutics
PIPE-791 是 Contineum Therapeutics 在研的 LPA1 受体拮抗剂，用于特发性肺纤维化（IPF）和慢性疼痛，目前处于全球 II 期临床阶段。
PIPE-791 是 Contineum Therapeutics 在研的 LPA1 受体拮抗剂，用于特发性肺纤维化（IPF）和慢性疼痛，目前处于全球 II 期临床阶段。
LPA1 受体（LPAR1）拮抗剂；口服小分子，可穿透血脑屏障
2 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
